SCHEMBL17599423

SCHEMBL17599423

Cc1cc(C)c(C)c(S(=O)(=O)Nc2cc(-c3ccc(F)c(C(=O)O)c3)cc3ccccc23)c1C

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ MEN1 O00255 1/20 0.56
▸ HPGD P15428 1/20 0.56
▸ CRHBP P24387 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ CRHR2 Q13324 1/20 0.56
▸ ACLY P53396 8/20 0.46
▸ MCL1 Q07820 4/20 0.44
▸ PTGER4 P35408 2/20 0.44
▸ PTGER2 P43116 1/20 0.43
▸ FABP4 P15090 4/20 0.42
▸ FABP5 Q01469 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599470 0.90 MEN1 (0.46) ALDH1A1HSD17B10KDM4EMEN1HPGD
SCHEMBL17599435 0.89 ALDH1A1 (0.57) ALDH1A1HSD17B10KDM4EMEN1HPGD
SCHEMBL17599483 0.88 MEN1 (0.56) ALDH1A1HSD17B10KDM4EMEN1HPGD
SCHEMBL17599467 0.84 KMT2A (0.55) ALDH1A1HSD17B10KDM4EMEN1HPGD
SCHEMBL17599358 0.84 ALDH1A1 (0.58) ALDH1A1HSD17B10KDM4EMEN1HPGD
SCHEMBL17599463 0.83 ALDH1A1 (0.57) ALDH1A1HSD17B10KDM4EMEN1HPGD
SCHEMBL17599466 0.83 KMT2A (0.51) ALDH1A1HSD17B10KDM4EMEN1HPGD
SCHEMBL17599510 0.82 KMT2A (0.53) ALDH1A1HSD17B10KDM4EMEN1HPGD
SCHEMBL17599429 0.81 KMT2A (0.51) ALDH1A1HSD17B10KDM4EMEN1HPGD
SCHEMBL17599431 0.78 KMT2A (0.50) ALDH1A1HSD17B10KDM4EMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2998295-A1 Aryl substituted naphthyl sulfonamide derivatives as keap-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP claimed
EP-2998295-A1 Aryl substituted naphthyl sulfonamide derivatives as keap-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP disclosed
EP-2998295-A1 Aryl substituted naphthyl sulfonamide derivatives as keap-1 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders SANOFI (FR) 2016-03-23 — — EP disclosed
Send feedback